This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
== Further reading == Carbone, Christine E.; Loveland, Anna B.; Gamper, Howard B.; Hou, Ya-Ming; Demo, Gabriel; Korostelev, Andrei A. (December 2021). "Time-resolved cryo-EM visualizes ribosomal translocation with EF-G and GTP". Nature Communications. 12 (1): 7236. doi:10.1038/s41467-021-27415-0. PMC 8668904.
According to Cantrell, the album's cover art featuring a heart surrounded by a black background was inspired by the heartbreak of Staley's death. Staley's former bandmates also thanked him in the album's liner notes. On September 6, 2011, Hank Williams III released his Attention Deficit Domination album and dedicated it to Staley. Staley's Alice in Chains bandmates have stated that one of the saddest aspects of his legacy is to hear him remembered primarily for his drug use rather than the other aspects of his personality. Kinney and Cantrell have also expressed their frustration over the Grammys ignoring Staley during their annual tribute to the musicians who have died in the past year. In 2013, Alice in Chains' drummer, Sean Kinney, added the initials "LSMS" on his drum kit, a tribute to Staley and the band's former bassist, Mike Starr, who died in 2011. The music video for Alice in Chains' 2013 single, "Voices", features a picture of Staley next to a photo of Nirvana's frontman, Kurt Cobain, at the 2:20 mark. Since Alice in Chains reunited, Jerry Cantrell started paying tribute to Staley before performing the song "Nutshell". Since 2011, Cantrell pays tribute to both Staley and Mike Starr before performing the song at concerts. In April 2017, Nancy Wilson revealed that she started writing the song "The Dragon" for Staley in the 1990s. The song was recorded in 2016 and is part of the EP of Wilson's new band, Roadcase Royale, released in 2017.
== Sustainable development == The Sustainable Development Index (SDI) measures the ecological efficiency of human development. Its impetus was a reaction to the UN's Human Development Index (HDI) which measures various indicators of development, but does not assess the sustainability of those underlying indicators. Countries with high human development and low ecological impact rise to the top of the SDI. Countries with low human development, and countries with high human development but high ecological impact, fall to the bottom of the SDI. The latest iteration of the index (2020) uses data from 2015, the most recent year for which data is available. In this ranking of 163 nations, Thailand ranked 44. Other ASEAN nations were ranked: Philippines, 26; Indonesia, 30; Vietnam, 42; Laos, 66; Cambodia, 77; Myanmar, 79; Malaysia, 109; Brunei, 139; and Singapore, lowest of all nations at 163.
=== Angiogenesis === Angiogenesis is an essential aspect of tumour development. In order for a tumour to grow and significantly increase in size, it must have a sufficient blood supply. If the tumour is unable to develop the blood supply it requires, cells within the tumour will begin to die and further growth will be halted. Angiogenic factors such as vascular endothelial growth factor (VEGF), stromal cell-derived factor 1 (SDF-1), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) are expressed by CAF to encourage the growth of new blood vessels. Some of these factors may also recruit cells that are vital to the angiogenic process, for instance SDF-1 attracts bone-marrow derived endothelial cells.
The four substrates of this enzyme are 1-deoxy-11-oxopentalenic acid, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. It products are pentalenolactone D, oxidised NADP+, and water. The starting ketone is made as part of the biosynthetic pathway to pentalenolactone in Streptomyces avermitilis.
Sources: en.wikipedia.org
== Early career == De Castro was born in Guarda, on 9 November 1878. He was part of the Constitutional junta that governed Portugal in 1915. He later served as Governor-General of Mozambique between 1915 and 1918. He was a prominent participant in the attempted coup of 11 January 1919 which took place after the assassination of Sidónio Pais.
La Colombe was founded by Todd Carmichael and JP Iberti in 1994 in the Rittenhouse Square neighborhood of Philadelphia. In 2015, Hamdi Ulukaya, founder of Chobani, purchased a share of the company. Ulukaya bought out private equity firm Goode Partners to gain his stake, and helped the company raise $28.5 million to fund plans for expansion. This purchase made La Colombe one of several small-scale coffee roasters that received large investments or were acquired outright in 2015. In July 2023, Keurig Dr Pepper invested $300 million in La Colombe in exchange for 33% of the company. In December 2023, Chobani fully acquired La Colombe for $900 million. As part of the deal, Keurig Dr Pepper had its 33% equity converted to a minority position in Chobani. Chobani took a $550 million loan to fund the acquisition.
== Death == Florey published his last scientific paper, co-written with Jennings, in 1967. He had written or co-written over two hundred papers. He died at his home at the provost's lodgings, of congestive heart failure on 21 February 1968. Although Florey was an agnostic, a funeral service was held in the St. Nicholas' parish church in Marston. A memorial plaque was placed on the outside wall near the entrance; the church refused to allow it to be placed inside because Florey had been so outspoken in his disbelief. A larger service at Westminster Abbey in London was attended by about 500 people. His remains were cremated.
Le continued developing patches for the game until the release of Counter-Strike 1.0, after which he stepped away from the main title and began work on a prototype for Counter-Strike 2. However, after nearly three years of development, the project was shelved when it was only about 25% complete. With Counter-Strike 2 discontinued, Minh Le turned his attention to developing Day of Defeat: Source. Following its release, he left Valve in 2006 to pursue an independent project. After spending two years working with a small team on the project, he moved to South Korea in 2008 to work with the company named FIX Korea, which provided funding for its continued development. Le's new game was later revealed to be Tactical Intervention, a game similar in style to Counter-Strike created with a modified version of Valve's Source engine. In October 2013, Minh Le joined Facepunch Studios, where he worked on Rust. He remained at the studio until February 2018, when he departed to join Pearl Abyss the following month. There, he worked on MMOFPS game called PLAN 8. Le left Pearl Abyss in 2023. Minh Le later continued working in small-team and independent game development. His later projects included Alpha Response, a tactical PvE shooter released in early access. In 2026, Le said he had considered returning to work on Counter-Strike 2, particularly on weapon animations and maps, while also stating that he believed Counter-Strike was "in a really good space".
Sources: en.wikipedia.org
Key improvements made after the Union with Ireland Act 1800 (39 & 40 Geo. 3. c. 67) included the illumination of the South Stack Lighthouse in 1809, the construction of a built-up harbour in 1810, and the addition of a substantial breakwater between 1848 and 1873. Although mail service through Holyhead was temporarily suspended in 1838 in favour of rail transport through Liverpool, the development of the north Wales coastal railway in 1850 led to its reinstatement.
=== Familial dysautonomia === Familial dysautonomia is a genetic condition that can be associated with a lack of overflow tears (alacrima) during emotional crying. Obstruction of the punctum, nasolacrimal canal, or nasolacrimal duct can cause even normal levels of the basal tear to overflow onto the face (epiphora), giving the appearance of constant psychic tearing. This can have significant social consequences.
== Examples == Strategies for improving platinum-based anticancer drugs usually involve changes in the neutral spectator ligands, changes in the nature of the anions (halides vs various carboxylates), or changes in the oxidation state of the metal (Pt(II) vs Pt(IV)). Nanotechnology has been explored to deliver platinum more efficiently in the case of lipoplatin, which is introduced into the tumor sites thereby reducing the chance of toxicity. Cisplatin was the first to be developed. Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%. This application of cisplatin was developed by pediatric oncologist Roger Packer in the early 1980s.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.